We are live on ! Find out more
IMMU

Immunomedics Inc
IMMU

Delisted

IMMU was delisted on the 22nd of October, 2020.

192 hedge funds and large institutions have $3.48B invested in Immunomedics Inc in 2018 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 79 increasing their positions, 51 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 19

90% more capital invested

Capital invested by funds: $1.83B → $3.48B (+$1.65B)

55% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 51

14% more funds holding

Funds holding: 168192 (+24)

13% more funds holding in top 10

Funds holding in top 10: 89 (+1)

36% less call options, than puts

Call options by funds: $118M | Put options by funds: $184M

Holders
192
Holders Change
+24
Holders Change %
+14.29%
% of All Funds
4.4%
Holding in Top 10
9
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+12.5%
% of All Funds
0.21%
New
44
Increased
79
Reduced
51
Closed
19
Calls
$118M
Puts
$184M
Net Calls
-$65.4M
Net Calls Change
-$72.2M
Name Holding Trade Value Shares
Change
Change in
Stake
ACA
1
Avoro Capital Advisors
New York
$419M +$15.6M +775,000 +5%
Vanguard Group
2
Vanguard Group
Pennsylvania
$335M +$113M +5,605,289 +65%
BlackRock
3
BlackRock
New York
$266M +$44.1M +2,195,066 +24%
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$208M +$36M +1,790,358 +26%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$201M +$14.1M +699,658 +9%
State Street
6
State Street
Massachusetts
$126M -$20M -996,270 -16%
O
7
OrbiMed
New York
$117M -$15.4M -766,201 -13%
PAI
8
Palo Alto Investors
California
$114M +$148K +7,356 +0.2%
ACP
9
Acuta Capital Partners
California
$112M -$22.1M -1,100,000 -19%
ACH
10
ArrowMark Colorado Holdings
Colorado
$102M -$12.8M -636,214 -13%
Millennium Management
11
Millennium Management
New York
$88.6M +$19.2M +956,801 +34%
Janus Henderson Group
12
Janus Henderson Group
United Kingdom
$76.2M +$25.8M +1,284,303 +66%
RCM
13
RA Capital Management
Massachusetts
$73.8M +$62.7M +3,119,778 New
FCMI
14
Foresite Capital Management III
California
$60.2M -$3.18M -158,271 -6%
Jennison Associates
15
Jennison Associates
New York
$50.8M +$707K +35,186 +2%
Victory Capital Management
16
Victory Capital Management
Texas
$49M +$4.01M +199,320 +11%
Alkeon Capital Management
17
Alkeon Capital Management
New York
$43.8M +$37.2M +1,850,000 New
Citadel Advisors
18
Citadel Advisors
Florida
$40.7M -$2.04M -101,687 -6%
Northern Trust
19
Northern Trust
Illinois
$40M +$8.71M +433,359 +34%
Geode Capital Management
20
Geode Capital Management
Massachusetts
$36.8M +$10.3M +510,544 +49%
American Century Companies
21
American Century Companies
Missouri
$36.6M +$31.1M +1,545,044 New
Lord, Abbett & Co
22
Lord, Abbett & Co
New Jersey
$34.1M +$10.2M +505,631 +54%
VOYA Investment Management
23
VOYA Investment Management
Georgia
$31.6M +$25.9M +1,288,515 +2,844%
NC
24
Nexthera Capital
New York
$31.5M +$4.98M +247,694 +23%
PAMU
25
Pictet Asset Management (UK)
United Kingdom
$30.9M -$5.93M -294,970 -18%

IMMU Hedge Fund Activity: Q2 2018 in Review

192 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q2 2018, worth a combined $3.48B — up 90% from $1.83B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new IMMU positions and 19 closed out — a net gain of 25 holders — while 79 added to existing stakes and 51 trimmed.

The largest buyer was Vanguard Group, adding an estimated $113M. The largest seller was NEA Management Company, exiting entirely with an estimated $40.5M sold.

  • 192 institutional investors held Immunomedics Inc (IMMU) as of Q2 2018, up from 168 in Q1 2018.
  • Funds reported $3.48B of Immunomedics Inc stock for Q2 2018, up 90% quarter-over-quarter.
  • 44 funds opened new Immunomedics Inc positions in Q2 2018 and 19 closed out, a net change of +25 holders.
  • The largest Immunomedics Inc buyer in Q2 2018 was Vanguard Group, an estimated $113M added.
  • The largest Immunomedics Inc seller in Q2 2018 was NEA Management Company, an estimated $40.5M sold.

Based on aggregated 13F filings for Q2 2018.